ABSTRACT
Osteoprotegerin (OPG) is a soluble decoy receptor for receptor activator of NF-ƙB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL), and is increasingly recognised as a marker of poor prognosis in a number of diseases. Here we demonstrate that in Malaysian adults with falciparum and vivax malaria, OPG is increased, and its ligands TRAIL and RANKL decreased, in proportion to disease severity. In volunteers experimentally infected with P. falciparum and P. vivax, RANKL was suppressed, while TRAIL was unexpectedly increased, suggesting binding of OPG to RANKL prior to TRAIL. We also demonstrate that P. falciparum stimulates B cells to produce OPG in vitro, and that B cell OPG production is increased ex vivo in patients with falciparum, vivax and knowlesi malaria. Our findings provide further evidence of the importance of the OPG/RANKL/TRAIL pathway in pathogenesis of diseases involving systemic inflammation, and may have implications for adjunctive therapies. Further evaluation of the role of B cell production of OPG in host responses to malaria and other inflammatory diseases is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Health and Medical Research Council (Program Grant 1037304, Project Grants 1045156 and 1156809; Investigator Grants 2016792 to BEB, 2016396 to JSM, 2017436 to MJG), the US National Institute of Health (R01 AI116472-03), and the Malaysian Ministry of Health (Grant BP00500420). The malaria volunteer infection studies were supported by Medicines for Malaria Venture.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were conducted in accordance with the Declaration of Helsinki and the International Committee of Harmonisation of Good Clinical Practice guidelines. All participants provided informed written consent. For the use of samples from the malaria volunteer infection studies and for the isolation of PBMCs from buffy coats obtained from Australian Red Cross Lifeblood, ethics approval was obtained from the Human Research Ethics Committee of the QIMR Berghofer Medical Research Institute (P1479 and P3444 respectively). For the clinical studies in Malaysia, ethics approval was obtained from the Malaysian Ministry of Health (NMRR10_754_6684) and the Menzies School of Health Research, Darwin, Australia (HREC 2010_1431). Informed written consent was provided by all participating adults and parents/guardians of those under 18 years of age.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability statement
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
